Goserelin

Generic Name: Goserelin

Brand Names: Zoladex

Drug Type: Small Molecule

Chemical Formula: C_₅₉H_₈₄N_₁₈O_₁₄

CAS Number: 65807-02-5

Unique Ingredient Identifier: 0F65R8P09N

Background: Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.

Indication: Goserelin is indicated for:

Associated Conditions: Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate

Associated Therapies: Palliative Treatment

Clinical Trials

Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate

Phase 2

Not yet recruiting

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone acetate
Drug: Prednisolone
Drug: Goserelin

First Posted Date: 2021-02-03

Last Posted Date: 2021-02-08

Lead Sponsor: West China Hospital

Target Recruit Count: 50

Registration Number: NCT04736108

Locations: 🇨🇳
West China Hospital, Chengdu, Sichuan, China

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Phase 2

Recruiting

Conditions: Stage IVB Prostate Cancer AJCC v8
Castration-Sensitive Prostate Carcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Metastatic Prostate Adenocarcinoma

Interventions: Drug: Abiraterone Acetate
Drug: Bicalutamide
Drug: Degarelix
Drug: Goserelin Acetate
Drug: Leuprolide Acetate
Drug: Prednisone
Other: Questionnaire Administration
Drug: Talazoparib

First Posted Date: 2021-02-02

Last Posted Date: 2025-01-03

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 70

Registration Number: NCT04734730

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)

Phase 2

Active, not recruiting

Conditions: Invasive Lobular Breast Carcinoma
ER+ Breast Cancer
HER2-negative Breast Cancer

Interventions: Drug: Entrectinib
Drug: Letrozole
Drug: Goserelin

First Posted Date: 2020-09-16

Last Posted Date: 2024-12-04

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 65

Registration Number: NCT04551495

Locations: 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇫🇷
Institut Bergonié, Bordeaux, France
🇧🇪
Grand Hôpital de Charleroi, Charleroi, Belgium

and more 7 locations

Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients

Phase 2

Conditions: Premature Ovarian Failure

Interventions: Drug: Chemotherapy
Drug: Goserelin

First Posted Date: 2020-09-02

Last Posted Date: 2024-03-19

Lead Sponsor: Beni-Suef University

Target Recruit Count: 80

Registration Number: NCT04536467

Locations: 🇪🇬
Beni Suef university, Fayoum, Mesala, Egypt

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Phase 3

Recruiting

Conditions: Metastatic Malignant Neoplasm in the Bone
Prostate Adenocarcinoma
Stage III Prostate Cancer AJCC v8
Stage IIIA Prostate Cancer AJCC v8
Stage IIIC Prostate Cancer AJCC v8
Stage IIIB Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8

Interventions: Drug: Bicalutamide
Drug: Apalutamide
Drug: Buserelin
Drug: Degarelix
Drug: Flutamide
Drug: Goserelin
Drug: Leuprolide
Drug: Histrelin
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Radiation Therapy
Drug: Triptorelin

First Posted Date: 2020-08-14

Last Posted Date: 2024-11-27

Lead Sponsor: NRG Oncology

Target Recruit Count: 2478

Registration Number: NCT04513717

Locations: 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸
Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
🇺🇸
Arizona Center for Cancer Care - Scottsdale, Scottsdale, Arizona, United States

and more 548 locations

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

Phase 3

Terminated

Conditions: Breast Cancer

Interventions: Drug: Amcenestrant-matching placebo
Drug: SAR439859
Drug: Palbociclib
Drug: Letrozole
Drug: Letrozole-matching placebo
Drug: Goserelin

First Posted Date: 2020-07-20

Last Posted Date: 2023-12-08

Lead Sponsor: Sanofi

Target Recruit Count: 1068

Registration Number: NCT04478266

Locations: 🇺🇸
Investigational Site Number :8400029, Santa Monica, California, United States
🇺🇸
Investigational Site Number :8400038, Fullerton, California, United States
🇺🇸
Investigational Site Number :8400013, Westwood, Kansas, United States

and more 246 locations

Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

Phase 4

Conditions: Prostatic Neoplasms

Interventions: Drug: Leuprorelin
Drug: Goserelin
Drug: Triptorelin
Drug: Degarelix
Drug: Bicalutamide
Drug: Flutamide
Drug: Maximum androgen blockade

First Posted Date: 2020-01-30

Last Posted Date: 2021-07-29

Lead Sponsor: Wonju Severance Christian Hospital

Target Recruit Count: 164

Registration Number: NCT04248621

Locations: 🇰🇷
Department of Urology, Chonnam National University, School of Medicine, Gwangju, Korea, Republic of
🇰🇷
Department of Urology, Kyungpook National University, School of Medicine, Daegu, Korea, Republic of
🇰🇷
Department of Urology, Eulji University, College of Medicine, Daejeon, Korea, Republic of

and more 7 locations

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Phase 1

Conditions: Melanoma (Skin)

Interventions: Drug: Peptide
Drug: Anti-PD-1
Drug: rhGM-CSF
Drug: Imiquimod 5% Topical Cream

First Posted Date: 2019-08-28

Last Posted Date: 2020-04-28

Lead Sponsor: Xiangya Hospital of Central South University

Target Recruit Count: 30

Registration Number: NCT04072900

Locations: 🇨🇳
Xiangya Hospital, Central South University, Changsha, Hunan, China

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Castrate Sensitive Prostate Cancer

Interventions: Drug: goserelin
Drug: Enzalutamide
Drug: Abiraterone
Drug: 18F-DCFPyL
Drug: Prednisone
Procedure: Radical Prostatectomy

First Posted Date: 2019-03-04

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT03860987

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Combination Product: Docetaxel / Capecitabine
Drug: Letrozole OR Anastrozole
Combination Product: Capecitabine / Vinorelbine
Combination Product: Paclitaxel / Gemcitabine
Drug: Goserelin

First Posted Date: 2019-02-15

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 223

Registration Number: NCT03839823

Locations: 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy